Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-20T06:41:49.020Z Has data issue: false hasContentIssue false
  • English
  • Français

Long-term studies in depression — relapse, recurrence, and reliability of outcome measures: Discussion

Published online by Cambridge University Press:  16 April 2020

JMA Sitsen
JMA Sitsen*
Affiliation:
NV Organon, PO Box 20, 5340BH Oss, The Netherlands
Get access

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Research Article
Information
European Psychiatry , Volume 11 , Issue 3: Issues of Concern in the Standardization and Harmonization of Psychotropic Drug Trials in Europe , 1996 , pp. 120 - 122
Copyright
Copyright © Elsevier, Paris 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Doogan, DP, Caillard, VSertraline in the prevention of depression. Br J Psychiatry 1992; 160: 217–222CrossRefGoogle ScholarPubMed
Greenhouse, JB, Stangl, D, Kupfer, D, Prien, RFMethodologic issues in maintenance therapy clinical trials. Arch Gen Psychiatry 1991; 48: 313–318CrossRefGoogle ScholarPubMed
Guidelines on psychotropic drugs for the EC. Eur Psychopharmacol 1994; 4: 61–77CrossRefGoogle Scholar
Montgomery, SAProphylaxis in recurrent unipolar depression: a new indication for treatment studies. J Psychopharmacol 1989; 3: 47–53CrossRefGoogle ScholarPubMed
Montgomery, SAPlacebo-controlled efficacy of antidepressants in continuation treatment Int Clin Psychopharmacol 1994 9 suppl 1 49–53CrossRefGoogle ScholarPubMed
Montgomery, SA, Dunbar, GCParoxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 1993; 8: 189–195CrossRefGoogle ScholarPubMed
Montgomery, SA, Rasmussen, JGC, Tanghoj, PA 24-week study of 20 mg citalopram, 40 mg citalopram an placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993; 9: 181–188CrossRefGoogle Scholar
Rouillon, F, Phillips, R, Serrurier, D, Ansarte, E, Gerard, MJRechutes de depression unipolaire et efficacité de la maprotiline. Encéphale 1989; 15: 527–534Google Scholar
Rouillon, F, Stern, L, Wood, SMethodological approaches to the long-term study of antidepressants. Eur Psychiatry 1996; 11: 109–115CrossRefGoogle ScholarPubMed
Sitsen, JMA, Montgomery, SAThe pharmacological treatment of depression and its problems In: Den Boer, JA, Sitsen, JMAHandbook of Anxiety and Depression — a Biological Approach Chichester: Marcel Dekker, 1994; 349–377Google Scholar
Submit a response

Comments

No Comments have been published for this article.